CClinicalTrials.gg
CompletedNCT06552390HRN4HTxUpdated Aug 14, 2024

Cardiac Rehabilitation for Inpatient Heart Transplant (HRN4HTx)

An interventional study of Cardiac Rehabilitation in Heart Transplantation, sponsored by Instituto Politécnico de Bragança. Completed at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by Instituto Politécnico de Bragança · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 7 months after the study started (first participant enrolled Jan 2019, registered Aug 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the safety and efficacy of the phase 1 cardiac rehabilitation protocol(HRN4HTx) in heart transplant patients, focusing on self-care capacity and functionalrecovery.

Read the detailed description

Type of study: Descriptive and Interventional Study

  • Location: Centro Hospitalar e Universitário de Coimbra, Cardiothoracic Surgery Unit

Study Population:

  • Inclusion Criteria: Heart transplant patients, over 18 years of age, capable of providing informed consent.
  • Exclusion Criteria: Rejection 2R, inability to understand due to cognitive impairment, external ventricular assistance, infectious processes with hemodynamic changes.

Intervention:

The HRN4HTx protocol was implemented during hospitalization, divided into five progressive stages according to FITT parameters and international recommendations. Interventions included respiratory exercises, calisthenics exercises, balance training, resistance exercises for upper and lower limbs, and walking.

Adverse Event Monitoring:

Adverse events (AEs) and serious adverse events (SAEs) were monitored according to Good Clinical Practices. Examples of monitored events include arrhythmias and significant changes in blood pressure.

Outcomes Measured:

  • Self-Care Capacity: Barthel Index measured at admission and discharge.
  • Functional Capacity: 6-minute walk test (6MWT) conducted at discharge.
  • Knowledge of Risk Factors: Evaluation of knowledge regarding alarm signs and cardiovascular risk factors at discharge.

Ethical Approval:

This study was approved by the Ethics Committee of the Centro Hospitalar e Universitáriode Coimbra (Protocol No. OBS.SF.111/2021). All participants provided written informed consent prior to participation.

02

Conditions studied

  • Heart Transplantation

Keywords

  • Cardiac Rehabilitation
  • Rehabilitation
  • Self Care
03

In context

Lead sponsor

Instituto Politécnico de Bragança is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Heart transplant patients, over 18 years of age, capable of providing informedconsent.

Exclusion criteria

Exclusion Criteria:

  • Rejection 2R
  • Inability to understand due to cognitive impairment
  • External ventricular assistance
  • Infectious processes with hemodynamic changes
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Intervention Group - HRN4HTx

    Cardiac rehabilitation as previously described.

    Procedure: Cardiac Rehabilitation

Interventions

  • ProcedureCardiac Rehabilitation

    HRN4HTx is a phase 1 rehabilitation intervention protocol for post-heart transplant focused on the physical exercise component, and an educational plan regarding risk factors and safety criteria. The intervention protocol and its assessments are implemented by the team's rehabilitation nurses, always safeguarding the protective isolation required for these patients. The physical training protocol is divided into five stages of progressive levels of intervention. The protocol was defined following FITT parameters, international recommendations, and an integrated teaching program aimed at the therapeutic regimen exercise area. The frequency of intervention sessions is 7 days a week, twice a day (average of 13 sessions per week) throughout the hospitalization. The intensity was defined according to Borg's modified scale of subjective perception of exertion (SPE), which must be maintained at less than 5.

06

What researchers measure

Primary outcomes

  1. Functional Capacity - Evaluation of the 6-minute walk test (6MWT)

    6-minute walk test (6MWT), higher value means better outcome (no maximum value)

    Time frame: At the date of discharge (mean days of hospitalization of 15 until a maximum of days 21)

  2. Self-Care Capacity - Evaluation of the Barthel Index

    Barthel Index, from 0 to 100, higher scores means better outcome

    Time frame: At the date of admission and at the date of discharge (mean days of hospitalization of 15 until a maximum of 21 days)

  3. Knowledge of Risk Factors - Evaluation of knowledge regarding alarm signs and cardiovascular risk factors

    Knowledge regarding alarm signs and cardiovascular risk factors, from 0 to 100%, higher value means better outcome

    Time frame: At the date of discharge (mean days of hospitalization of 15 until a maximum of 21 days)

07

Study locations

1 site
  • Unidade Local de Saúde de Coimbra
    Coimbra, 3000, Portugal
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06552390
Lead sponsor
Instituto Politécnico de Bragança
Collaborators
Unidade Local de Saúde de Coimbra, Universidade do Porto
Responsible party
André Filipe Morais Pinto Novo (Coordinator Professor, Instituto Politécnico de Bragança) — Principal investigator
First posted
Aug 14, 2024
Start date
Jan 1, 2019
Primary completion
Jan 1, 2024
Completion
Jan 1, 2024
Last update
Aug 14, 2024

Study contacts

André Novo, PhD.
study director · Instituto Politécnico de Bragança

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion